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Background:  Emerging evidence implicates the soluble receptor for advanced glycation end-products (sRAGE) in the development of vascular 
disease, while arterial stiffening, urinary albumin excretion and impaired renal function are associated with atherosclerosis progression. In this study 
we estimated the relationships of sRAGE with albumin to creatinine ratio (ACR), estimated glomerular filtration rate (eGFR) and arterial stiffness in 
essential hypertension.
Methods:  In 320 newly diagnosed untreated non-diabetic patients with stage I to II essential hypertension [192 men, mean age=52 years, office 
blood pressure (BP)=145/93 mmHg] ACR values were determined as the mean of two non-consecutive morning spot urine samples and aortic 
stiffness was evaluated on the basis of carotid to femoral pulse wave velocity (PWV). Moreover, eGFR was assessed using the Modification of Diet in 
Renal Disease equation, while the distribution of sRAGE was split by the median (1060.1 pg/ml) and accordingly subjects were stratified into those 
with high and low values.
Results:  Patients with low sRAGE (n=164) compared to those with high sRAGE values (n=156) had greater 24-h systolic BP (139±8 vs 131±6 
mmHg, p=0.001), while did not differ regarding metabolic profile (p=NS). Moreover, patients with low compared to those with high sRAGE levels 
exhibited higher ACR (50.56±14.3 vs 20.75±15.5 mg/g, p=0.011) and PWV (9±1.7 vs 7.5±1.2 m/sec, p<0.0001), whereas had lower eGFR 
(65.9±7.2 vs 92.6±9.1 ml/min/1.73m2, p<0.05), independently of confounders. In the total population, sRAGE was associated with 24-h pulse 
pressure (r=-0.371, p=0.001), ACR (r=-0.274, p=0.019), eGFR (r=0.236, p=0.03) and PWV (r=-0.401, p<0.0001). Multiple regression analysis 
revealed that body mass index, 24-h systolic BP, ACR and PWV were the independent predictors of sRAGE (R2=0.57, p<0.0001).
Conclusion: In essential hypertension, decreased sRAGE levels are associated with increased PWV, pronounced albuminuria and impairment of 
renal function. Moreover, the close relation of sRAGE with arterial stiffening, ACR and eGFR, supports the potent role of sRAGE in renal and vascular 
atherosclerotic disease progression.
